Skip to main content
main-content

08-06-2018 | Pancreatic cancer | ASCO 2018 | Video

Researcher comment: Neoadjuvant chemoradiotherapy beneficial for resectable pancreatic cancer

Preliminary findings from the PREOPANC -1 trial suggest that neoadjuvant chemoradiotherapy may be beneficial for patients with resectable pancreatic cancer. Lead author Geertjan Van Tienhoven outlines the results and discusses the challenges of conducting this trial. (3:46)

Watch the accompanying expert commentary.

Please log in to get access to this content

More on this topic

image credits